Last reviewed · How we verify
NCT06619886
TP53 R248Q TCR-T Cell Therapy for Advanced Solid Tumor
EARLY_PHASE1 trial testing Autologous, engineered T Cells targeting TP53 R248Q in Solid Tumor, Adult in 9 participants. Not yet recruiting.
31 October 2026
Quick facts
| Lead sponsor | Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine |
|---|---|
| Phase | EARLY_PHASE1 |
| Status | Not yet recruiting |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 9 |
| Start date | 24 September 2024 |
| Primary completion | 31 October 2026 |
| Estimated completion | 31 October 2027 |
| Sites | 1 location across China |
Drugs / interventions tested
- Autologous, engineered T Cells targeting TP53 R248Q — full drug profile →
Conditions studied
- Solid Tumor, Adult — all drugs for Solid Tumor, Adult →
- Lung Adenocarcinoma — all drugs for Lung Adenocarcinoma →
- Pancreas Cancer — all drugs for Pancreas Cancer →
- Colorectal Cancer — all drugs for Colorectal Cancer →
Sponsor
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Who can join
Adults 18 to 75, any sex, with Solid Tumor, Adult or Lung Adenocarcinoma. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
To evaluate the safety and efficacy of T cell therapy with mutated TP53 R248Q specific TCR transduction in patients with advanced solid tumor expressing the TP53 R248Q mutation and the HLA-A\*11:01 allele.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Emerging Therapeutic Approaches to Pancreatic Adenocarcinoma: Advances and Future Directions.
Peng C, Oberstein PE. · · 2025 · cited 1× · PMID 40884689 · DOI 10.1007/s11864-025-01352-2
Verify or expand the search:
- PubMed search for NCT06619886
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Solid Tumor, Adult
Currently open trials in the same condition.
- NCT07139990 — Personalized Radiotherapy for Individualized Treatment Strategies and Monitoring (PRISM) · Phase 1 · recruiting
- NCT06398418 — R-5780-01 In Combination With PD-1 Checkpoint Inhibitors (Checkpoint Protein on Immune Cells Called T Cells) in Patients · Phase 1 · recruiting
- NCT06682793 — A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumor · Phase 1, PHASE2 · recruiting
- NCT07137195 — Clinical Trial of the Safety and Efficacy of IBA Proton Therapy System PROTEUS® PLUS (Hebei) · NA · active not recruiting
- NCT06714617 — Evaluate BL-M17D1 in Patients w/HER2-Expressing/Mutant Advanced or Metastatic Solid Tumors · Phase 1 · active not recruiting
Other Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine trials
Trials by the same sponsor.
- NCT06667466 — New Laser and Suction Sheath for Kidney Stone Treatment · not yet recruiting
- NCT07043374 — Impact of Humid-Heat on Gut-Tryptophan-Stone Pathway · not yet recruiting
- NCT07415226 — Glucose-lowering Drugs as an Adjunct to Insulin Therapy in Chinese Patients With Type 1 Diabetes · not yet recruiting
- NCT07469046 — VAH vs VA in Newly Diagnosed Elderly AML · Phase 3 · not yet recruiting
- NCT07439120 — Safety and Tolerability Study of 68Ga/177Lu-BRP-020063 in Advanced Solid Tumors · EARLY_PHASE1 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06619886 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
- Last refreshed: 1 October 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06619886.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing